<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866615</url>
  </required_header>
  <id_info>
    <org_study_id>OCT&amp;OCTA in SLE</org_study_id>
    <nct_id>NCT04866615</nct_id>
  </id_info>
  <brief_title>Posterior Segment Evaluation of Patients With SLE Using OCT and OCTA</brief_title>
  <official_title>Posterior Segment Evaluation of Patients With Systemic Lupus Erythematosus Using Optical Coherence Tomography and Optical Coherence Tomography Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of The Study To evaluate different structural retinal changes using OCT and OCT-A in&#xD;
      patients with SLE ; newly diagnosed patients and patients on treatment and compare parameters&#xD;
      with normal subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory&#xD;
&#xD;
      disease that involves different organs and systems. The heterogeneous nature of&#xD;
&#xD;
      the disease represents a great challenge in its diagnosis and management. Studies&#xD;
&#xD;
      reported that the percentage of SLE patients demonstrating ocular manifestations&#xD;
&#xD;
      can reach up to 30%.&#xD;
&#xD;
      The pathogenesis of the ocular involvement is still unclear, but immune&#xD;
&#xD;
      complex vasculopathy and inflammatory mediators might be implicated. The most&#xD;
&#xD;
      common ocular manifestation in SLE was found to be kerato-conjunctivitis&#xD;
&#xD;
      sicca(KCS) followed by retinopathy, where is the most severe manifestation was&#xD;
&#xD;
      the optic nerve involvement, which might end up with irreversible blindness while&#xD;
&#xD;
      anterior uveitis is a rare manifestation in SLE.&#xD;
&#xD;
      Retinal involvement can vary from subclinical vascular changes to vaso-&#xD;
&#xD;
      occlusive vision-threatening retinopathy. Lupus retinopathy is secondary to IgG&#xD;
&#xD;
      complex-mediated micro-angiopathy that leads to small vessels infarcts. Currently,&#xD;
&#xD;
      there is no agreement on existing biomarkers to identify SLE patients who have&#xD;
&#xD;
      subclinical retinal involvement, or to identify whether micro-vascular changes in&#xD;
&#xD;
      the retina are attributable to SLE. Lupus retinopathy is usually associated with&#xD;
&#xD;
      high disease activity especially nephritis and cerebritis.&#xD;
&#xD;
      On the other side, hydroxychloroquine,(HCQ) a cornerstone in lupus treatment, rarely causes&#xD;
      ocular toxicity at doses of less than 6.5 mg/kg per day. Moreover, HCQ is found to be&#xD;
      associated with retinopathy after a prolonged time of treatment (&gt;5 years).&#xD;
&#xD;
      HCQ binds to melanin pigments in the retinal pigment epithelium (RPE). This binding may serve&#xD;
      to concentrate the agents in the cell and contribute to their long-term effects. The classic&#xD;
      pattern of retinal toxicity of HCQ is RPE depigmentation with foveal sparing, known as&#xD;
      bull's-eye maculopathy. Although visual acuity in these patients seems intact, patients&#xD;
      complain from para-central scotomas associated with reading difficulties. Besides, reduced&#xD;
      color perception can be seen as retinopathy symptoms. That is why it is important to evaluate&#xD;
      the eyes before starting therapy and during follow-up visits.&#xD;
&#xD;
      Modern imaging techniques have provided easier and more accurate evaluation as Optical&#xD;
      coherence tomography (OCT) is a noninvasive imaging technology, which picks up&#xD;
      cross-sectional pictures of the retinal layers, detect thinning of retinal nerve fiber layer&#xD;
      and macula.&#xD;
&#xD;
      Optical coherence tomography angiography (OCTA) is a relatively new technique that allows&#xD;
      visualization of the retina capillary bed and its subtle changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of vessel density</measure>
    <time_frame>3 months</time_frame>
    <description>comparison of vessel density of superficial and deep layers of retina in 150 subjects divided into 3 groups newly diagnosed SLE patients and SLE patients on treatment and normal subjects using OCT Angiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of foveal avascular zone</measure>
    <time_frame>3 months</time_frame>
    <description>1) comparison of foveal avascular zone between 3 groups using OCT Angiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of macular thickness</measure>
    <time_frame>3 months</time_frame>
    <description>comparison of macular thickness between 3 groups using OCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement thickness of retinal nerve fiber layer</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of thickness of retinal nerve fiber layer between the 3 groups using OCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of thickness of ganglion cell layer complex</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of thickness of ganglion cell layer complex between the 3 groups using OCT.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>SLE (Systemic Lupus)</condition>
  <arm_group>
    <arm_group_label>50 patients newly diagnosed SLE with no treatment</arm_group_label>
    <description>OCT &amp; OCTA for newly diagnosed SLE patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 patients SLE on treatment by (HCQ) at doses of less than 6.5 mg/kg per day for less than 5 years</arm_group_label>
    <description>OCT &amp; OCTA for on treatment SLE patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 normal subjects as control group of similar age and gender</arm_group_label>
    <description>OCT &amp; OCTA for normal subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optvue OCT</intervention_name>
    <description>Optical coherence tomography</description>
    <arm_group_label>50 normal subjects as control group of similar age and gender</arm_group_label>
    <arm_group_label>50 patients SLE on treatment by (HCQ) at doses of less than 6.5 mg/kg per day for less than 5 years</arm_group_label>
    <arm_group_label>50 patients newly diagnosed SLE with no treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of Minia Governorate diagnosed with SLE and healthy one&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18 years old.&#xD;
&#xD;
          2. Patients with SLE diagnosed by a Rheumatologist with no ocular involvement upon&#xD;
             clinical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of intraocular surgery as cataract surgery retinal detachment&#xD;
             surgery and anti-glaucoma surgery.&#xD;
&#xD;
          2. Patients with significant media opacity as corneal opacity, cataract.&#xD;
&#xD;
          3. Patients with ocular diseases as glaucoma, uveitis.&#xD;
&#xD;
          4. Patients with any retinal affection as pathological myopia, macular hole, age related&#xD;
             macular degeneration and retinal vascular occlusion.&#xD;
&#xD;
          5. Patients with systemic diseases as diabetes mellitus (DM), hypertension, abnormal&#xD;
             kidney functions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azza Shehab, MD</last_name>
    <role>Study Director</role>
    <affiliation>Minia University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Farouk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Minia University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Salah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Minia University hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazem Mohamed, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minia University hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hazem Mohamed, Resident</last_name>
    <phone>+201010045499</phone>
    <email>dr.hazemmohamed2013@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Salah, MD</last_name>
    <phone>01003321802</phone>
    <email>drmsalah1982@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Minia university hospital</name>
      <address>
        <city>Minya</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hazem Mohamed, Resident</last_name>
      <phone>01010045499</phone>
      <email>dr.hazemmohamed2013@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Larosa M, Iaccarino L, Gatto M, Punzi L, Doria A. Advances in the diagnosis and classification of systemic lupus erythematosus. Expert Rev Clin Immunol. 2016 Dec;12(12):1309-1320. Epub 2016 Jul 8. Review.</citation>
    <PMID>27362864</PMID>
  </reference>
  <reference>
    <citation>Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol. 2016 Apr-Jun;30(2):117-21. doi: 10.1016/j.sjopt.2016.02.001. Epub 2016 Feb 16. Review.</citation>
    <PMID>27330388</PMID>
  </reference>
  <reference>
    <citation>El-Shereef RR, Mohamed AS, Hamdy L. Ocular manifestation of systemic lupus erythematosus. Rheumatol Int. 2013 Jun;33(6):1637-42. doi: 10.1007/s00296-011-2296-x. Epub 2011 Dec 28.</citation>
    <PMID>22202921</PMID>
  </reference>
  <reference>
    <citation>Kahwage PP, Ferriani MP, Furtado JM, de Carvalho LM, Pileggi GS, Gomes FH, Terreri MT, MagalhÃ£es CS, Pereira RM, Sacchetti SB, Marini R, BonfÃ¡ E, Silva CA, Ferriani VP. Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey. Clin Rheumatol. 2017 Mar;36(3):547-553. doi: 10.1007/s10067-016-3534-0. Epub 2017 Jan 9.</citation>
    <PMID>28070763</PMID>
  </reference>
  <reference>
    <citation>Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007 Dec;46(12):1757-62. Epub 2007 Aug 5. Review.</citation>
    <PMID>17681981</PMID>
  </reference>
  <reference>
    <citation>Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol. 2012;6:377-83. doi: 10.2147/OPTH.S27731. Epub 2012 Mar 8.</citation>
    <PMID>22457587</PMID>
  </reference>
  <reference>
    <citation>Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun;123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16.</citation>
    <PMID>26992838</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Hazem Mohamed Mohamed</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

